Skip to main content

Table 4 Multivariable analysis of risk factors for analyses examining PFS or OS for all-comers

From: SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

CategoryPFS from start of first-line therapy (n = 253)PFS from start of second-line therapy (n = 88)OS from index date (n = 370)
HR95% CIP valueHR95% CIP valueHR95% CIP value
PD-L1 expression high vs lowa1.09(0.78–1.52)0.630.58(0.30–1.13)0.111.04(0.79–1.37)0.790
Age < 60 vs ≥ 60 years0.89(0.67–1.18)0.400.82(0.45–1.47)0.500.71(0.55–0.92)0.008
Race Caucasian vs other0.59(0.38–0.9)0.020.61(0.30–1.23)0.160.92(0.62–1.37)0.689
Nonsmoker vs current/former smoker0.81(0.55–1.21)0.310.97(0.47–2.01)0.931.20(0.85–1.69)0.292
Heavy alcohol use, no vs yes0.97(0.57–1.66)0.901.11(0.39–3.14)0.851.33(0.80–2.19)0.268
Metastatic disease, no vs yes1.27(0.96–1.68)0.100.59(0.34–1.03)0.061.42(1.10–1.84)0.008
Platinum-based therapy, no vs yes1.10(0.68–1.79)0.703.084(0.64–14.81)0.160.70(0.52–0.94)0.018
Anatomical site vs oral cavity
 Overlapping lesion1.05(0.47–2.33)0.910.82(0.16–4.10)0.811.25(0.65–2.38)0.503
  1. Statistically significant P values are in italics
  2. aPatients with PD-L1 result N = 396
  3. CI confidence interval, HR hazard ratio, OS overall survival, PD-L1 programmed cell death ligand-1, PFS progression-free survival